1. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
- Author
-
Lee MG, Wynder C, Schmidt DM, McCafferty DG, and Shiekhattar R
- Subjects
- Amidohydrolases antagonists & inhibitors, Amidohydrolases metabolism, Antidepressive Agents chemistry, Cell Line, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Humans, Methylation drug effects, Molecular Structure, Monoamine Oxidase metabolism, Monoamine Oxidase Inhibitors chemistry, Monoamine Oxidase Inhibitors pharmacology, Nucleosomes drug effects, Nucleosomes metabolism, Tranylcypromine pharmacology, Antidepressive Agents pharmacology, Histones chemistry, Histones metabolism, Lysine metabolism
- Abstract
Demethylation of histone H3 lysine 4 is carried out by BHC110/LSD1, an enzyme with close homology to monoamine oxidases (MAO). Monoamine oxidase A or B are frequent targets of selective and nonselective small molecular inhibitors used for treatment of depression. Here we show that in contrast to selective monoamine oxidase inhibitors such as pargyline, nonselective monoamine oxidase inhibitors potently inhibit nucleosomal demethylation of histone H3 lysine 4. Tranylcypromine (brand name Parnate) displayed the best inhibitory activity with an IC50 of less than 2 microM. Treatment of P19 embryonal carcinoma cells with tranylcypromine resulted in global increase in H3K4 methylation as well as transcriptional derepression of two BHC110 target genes, Egr1 and the pluripotent stem cell marker Oct4. These results attest to the effectiveness of tranylcypromine as a small molecular inhibitor of histone demethylation.
- Published
- 2006
- Full Text
- View/download PDF